Battling Cancer

One of the world’s most costly cancer drugs will not be marketed in Canada because of a price dispute between the drug’s distributor and the federal government.

The colorectal cancer drug Erbitux, which was approved by Health Canada nine months ago, will not be launched after distributor Bristol Myers Squibb Canada could not agree on a price with the federal Patented Medicine Prices Review Board., The Globe and Mail reports.

…..

While Erbitux has not yet been proven to extend the lives of colorectal cancer patients, it does shrink tumours in some patients and delay tumour growth, especially when used as a combination treatment.

MORE: CTV.ca | Price dispute blocks costly cancer drug in Canada